Speaker Profile

Ph.D., National Segment Director, Neurology, Specialty Medicine, University of North Texas Health Science Center

Biography
Dr. O’Bryant is the Executive Director of the UNTHSC Institute for Translational Research and Endowed Chair in Pharmacology and Neuroscience. He has spent his entire career working towards the development and implementation of a precision medicine model for advanced diagnostics and therapeutics to better the lives of those suffering from Alzheimer’s disease and other neurodegenerative diseases. He created the AD Blood Test for primary care doctors, which has been validated across multiple cohorts, technologies as well as human and animal models. He has also created a Parkinson’s Disease Blood Test for primary care, a Dementia with Lewy Bodies Blood Test for primary care, as well as an AD Blood Test for adults with Down Syndrome for primary care. He has created multiple technologies to identify subsets of patients suffering from Alzheimer’s disease (and other neurodegenerative diseases) that will benefit from targeted interventions. He is the PI of the HABLE study, which is a community-based study of Alzheimer’s Disease pathology among a multi-ethnic cohort with the goal of identifying and eliminating health disparities through a precision medicine approach. He is PI of the Alzheimer’s Disease in Primary Care (ADPC) study, which is the first-ever study of blood-based biomarkers for screening AD in primary care settings. He has published approximately 200 peer-reviewed publications and has been responsible for nearly $100m in funded research and clinical programs.


 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative